Current Price
$90.54
PE Ratio (TTM)
n/m
Intrinsic Value
Use the calculator below to estimate
COMPETITIVE MOAT
↑mRNA Technology Leadership
BioNTech's pioneering mRNA platform offers a significant technological advantage. This expertise allows for rapid development and adaptation of novel therapeutics and vaccines.
↑Strategic Partnerships
Collaborations with major pharmaceutical companies like Bristol Myers Squibb expand BioNTech's reach and validate its pipeline. These partnerships accelerate clinical trials and market access.
↑Oncology Pipeline Depth
A robust and diverse oncology pipeline, including promising bispecific candidates like pumitamig, demonstrates BioNTech's commitment to a critical therapeutic area. This diversification reduces reliance on single products.
INVESTMENT RISKS
↓Regulatory Hurdles
The biotechnology industry faces stringent regulatory approval processes. Delays or rejections for key drug candidates can significantly impact revenue and growth prospects.
↓Competition in Oncology
The oncology market is highly competitive with numerous established and emerging players. BioNTech's pipeline faces pressure from existing treatments and new entrants.
↓Dependence on Key Partnerships
While partnerships are a strength, over-reliance on a few major collaborators creates risk. Changes in partner strategies or financial health could disrupt development and commercialization.
Customize the BNTX PE valuation
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for BioNTech SE respond.
Open PE Calculator for BNTXCompany Overview
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Financial Metrics — BNTX PE Stock Valuation Data
PE Ratio (TTM)
n/m
PEG Ratio
0.16
Earnings Yield
-6.30%
ROE (TTM)
-6.7%
Revenue/Share (TTM)
$11.04
Debt/Equity
0.02x
Frequently Asked Questions
What is the PE ratio of BNTX?
The trailing twelve-month PE ratio of BNTX reflects how much investors pay per dollar of BioNTech SE's earnings. This metric is most useful when compared to Biotechnology peers and the company's own historical range.
Is BNTX overvalued based on PE ratio?
BNTX's PE of -15.9x combined with a PEG ratio of 0.16 provides a growth-adjusted perspective. A PEG below 1.0 suggests BNTX may be undervalued relative to its earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Biotechnology, a DCF analysis may be more appropriate.
How do I value BNTX stock using PE ratio?
To value BioNTech SE using PE: (1) Compare the current PE (-15.9x) against the Biotechnology median to assess relative pricing, (2) check the PEG ratio (0.16) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
What is the PEG ratio of BNTX?
BNTX's PEG ratio is 0.16, calculated by dividing the PE ratio (-15.9x) by the expected earnings growth rate. A PEG below 1.0 is traditionally considered a sign of undervaluation — the market may not be fully pricing in the growth potential. Note that PEG accuracy depends on the reliability of growth estimates.
Should I use PE ratio or DCF for BNTX stock valuation?
PE ratio gives a quick relative read — how BNTX is priced versus Biotechnology peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
Learn More
- See BNTX DCF Valuation → — Intrinsic value via Discounted Cash Flow analysis
- PE Methodology — Step-by-step guide to PE ratio stock valuation
- DCF Methodology — Guide to discounted cash flow analysis
- PE Ratio — Understanding the price-to-earnings ratio
- Intrinsic Value — How to evaluate stock fair value
Related PE Valuations
All Healthcare valuationsP/E and DCF value BNTX with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-06-12. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.